Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhaled corticosteroids for cystic fibrosis.

C Dezateux1, S Walters, I Balfour-Lynn

  • 1Department of Epidemiology and Public Health, Institute of Child Health, 30 Guildford Street, London, UK, WC1N 1EH. c.dezateux@ich.ucl.ac.uk

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"In My Community, if You're an Addict, People Don't Just Look Down on You for the Drugs, but for Being Black, Too": Black and Latine Methadone Patients' Experiences Around Addiction, Methadone Treatment, and Intersectional Stigma.

Journal of racial and ethnic health disparities·2026
Same author

Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC).

ESMO real world data and digital oncology·2026
Same author

The give and take of social support in professional athlete career pathways.

Journal of sports sciences·2026
Same author

Acute exertional compartment syndrome of the supraspinatus.

Annals of the Royal College of Surgeons of England·2025
Same author

Emerging athletes' career transitions in professional sport: an existential multi-case perspective.

Frontiers in sports and active living·2024
Same author

The accuracy of prehospital triage decisions in English trauma networks - a case-cohort study.

Scandinavian journal of trauma, resuscitation and emergency medicine·2024

Inhaled corticosteroids (ICS) offer potential benefits for cystic fibrosis (CF) patients by reducing lung inflammation. However, evidence on their effectiveness and safety is limited due to trial heterogeneity and insufficient data on key outcomes.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Medical Therapeutics

Background:

  • Optimal lung function is crucial in cystic fibrosis (CF) management, as lung damage causes most premature deaths.
  • Inhaled corticosteroids (ICS) are increasingly used in CF to mitigate inflammation-induced lung damage.
  • The potential benefits and harms of chronic ICS use in CF require thorough evidence assessment.

Purpose of the Study:

  • To evaluate the effectiveness of regular inhaled corticosteroid (ICS) use versus no ICS in cystic fibrosis (CF) patient management.
  • To synthesize current evidence on the benefits and risks associated with ICS therapy in CF.

Main Methods:

  • Systematic review of published and unpublished randomized and quasi-randomized controlled trials.
  • Searches included specialized registers (e.g., Cochrane Cystic Fibrosis and Genetic Disorders), databases (Medline, Embase), and manufacturer contact.

Related Experiment Videos

  • Outcomes assessed included lung function, exacerbations, antibiotic use, hospital admissions, nutritional status, quality of life, survival, and adverse effects.

    • Main Results:

    • Nine trials involving 266 subjects (aged 7-45) were identified, but methodological quality was often difficult to assess.
    • Significant heterogeneity existed in trial inclusion criteria, treatment types, and durations, precluding data pooling for lung function measures.
    • Crucial outcomes like nutritional status, quality of life, and survival were largely unreported; adverse effects were documented in only two trials.

    Conclusions:

    • The current evidence base on inhaled corticosteroid (ICS) effectiveness in cystic fibrosis (CF) is limited by trial heterogeneity and poor reporting of key outcomes.
    • Further high-quality research is needed to definitively establish the benefits and risks of ICS therapy in CF patients.
    • Insufficient data prevents firm conclusions regarding the impact of ICS on lung function, exacerbations, or long-term outcomes in CF.